These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36507829)

  • 21. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
    Liu XL; Pan Q; Zhang RN; Shen F; Yan SY; Sun C; Xu ZJ; Chen YW; Fan JG
    World J Gastroenterol; 2016 Nov; 22(44):9844-9852. PubMed ID: 27956809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit®.
    Belcaro G; Saggino A; Cornelli U; Luzzi R; Dugall M; Hosoi M; Feragalli B; Cesarone MR
    J Neurosurg Sci; 2018 Aug; 62(4):423-427. PubMed ID: 29938480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.
    Sangineto M; Bukke VN; Bellanti F; Tamborra R; Moola A; Duda L; Villani R; Romano AD; Serviddio G
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33671262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial.
    Panahi Y; Kianpour P; Mohtashami R; Atkin SL; Butler AE; Jafari R; Badeli R; Sahebkar A
    Phytother Res; 2018 Jul; 32(7):1382-1387. PubMed ID: 29520889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of diffuse, minimal lymphatic "retention" with Robuvit®: a concept, supplement registry study.
    Hu S; Belcaro G; Hosoi M; Cesarone MR; Scipione V; Scipione C; Dugall M; Feragalli B; Cotellese R; Maione C
    Minerva Cardioangiol; 2020 Jun; 68(3):197-202. PubMed ID: 32586070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
    Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
    Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
    S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mononucleosis-related fatigue: supplementary management with Robuvit®.
    Hu S; Belcaro G; Ledda A; Corsi M; Cotellese R; Feragalli B; Hosoi M; Dugall M; Torino-Rodriguez P; Cesarone MR
    Minerva Pediatr; 2018 Oct; 70(5):425-429. PubMed ID: 30302988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SHOULD ROUTINE LIVER BIOPSY BE CONSIDERED IN BARIATRIC SURGICAL PRACTICE? AN ANALYSIS OF THE LIMITATIONS OF NON-INVASIVE NAFLD MARKERS.
    Concon MM; Gestic MA; Utrini MP; Chaim FDM; Chaim EA; Cazzo E
    Arq Gastroenterol; 2022; 59(1):110-116. PubMed ID: 35442320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.